CAT #: 72250009
LymphoTrack® TRB Assay Kit A - MiSeqTM
This Research Use Only assay identifies clonal TRB Vβ-(Dβ-)Jβ rearrangements, the associated Vβ-(Dβ-)Jβ region DNA sequences and provides the frequency distribution of Vβ, Dβ, and Jβ region segment utilization using the Illumina® MiSeq platform.
Analysis of the TRB locus increases the probability of identifying T-cell receptor gene rearrangements, as compared to testing for TRG gene rearrangements only. As a result, combining the analysis of TRB and TRG loci increases the sensitivity of clonality detection.
Summary and Explanation of the Test
This LymphoTrack TRB Assay – MiSeq represents a significant improvement over existing clonality assays using fragment analysis as it efficiently detects the majority of TRB gene rearrangements using a single multiplex master mix, and at the same time, identifies the DNA sequence specific for each clonal gene rearrangement. Therefore, this assay has two important and complementary uses: it both aids in the detection of initial clonal populations and identifies sequence information required to track those clones in subsequent samples.
Each single multiplex master mix for TRB targets the conserved regions within the Vβ and the Jβ regions described in lymphoid malignancies. Primers included in the master mixes are designed with Illumina adapters and up to 8 different indices. This allows for a one-step PCR reaction and pooling of amplicons from several different samples and targets (generated with other LymphoTrack Assays for the Illumina MiSeq instrument, sold separately), onto one MiSeq flow cell allowing for up to 24 samples per target to be analyzed in parallel in a single run.
The associated LymphoTrack Software – MiSeq provides a simple and streamlined method of analysis and visualization of data.
Positive and negative controls for clonality are included in the kit.
Note: For a more thorough explanation of the locus and the targeted deep sequencing strategy, please refer to Principle of Immunoglobulin and T-Cell Receptor Gene Rearrangement.1
Principles of the Procedure
The human T-cell receptor beta (TRB, previously known as TCRB) gene locus on chromosome 7 (7q34) includes 65 Vβ (variable) gene segments, followed by two separate clusters of genes each containing a Dβ (diversity) gene, several Jβ (joining) genes, and a Cβ (constant) region spread over 685 kilobases. The two Cβ genes, TRBC1 and TRBC2, encode highly homologous products with no functional differences.
Lymphoid cells are different from the other somatic cells in the body. During development, the antigen receptor genes in lymphoid cells undergo somatic gene rearrangement.2 For example, during T-cell development genes encoding the TRB molecules are assembled from multiple polymorphic gene segments that undergo rearrangements and selection, generating Vβ–Dβ–Jβ combinations that are unique in both length and sequence. Since leukemias and lymphomas originate from the malignant transformation of individual lymphoid cells, all leukemias and lymphomas generally share one or more cell-specific or “clonal” antigen receptor gene rearrangements. Therefore, tests that detect TRB clonal rearrangements can be useful in the study of B- and T-cell malignancies.
Initially, clonal rearrangements were identified using Restriction Fragment, Southern Blot Hybridization (RF‑SBH) techniques. However, these tests proved cumbersome, labor-intensive, required large amounts of DNA, and were not suitable for analysis of many of the less diverse antigen receptor loci. During the last several decades, the use of RF-SBH assays has been supplanted by PCR-based clonality tests developed by Alexander Morley,3 and are considered the current gold standard method. PCR-based assays identify clonality on the basis of over-representation of amplified V–D–J (or incomplete D–J) products following their separation using gel or capillary electrophoresis. Though sensitive and suitable for testing small amounts of DNA, these assays cannot readily differentiate between clonal populations and multiple rearrangements that might lie beneath a single-sized peak and are not designed to identify the specific V–J DNA sequence that is required to track clonal populations in subsequent analyses. This second limitation can be of particular importance, as once the unique clone-specific DNA sequence is identified, the sequence can be used in subsequent tests to track and follow the clonal cell populations.
Polymerase Chain Reaction (PCR)
PCR assays are routinely used for the identification of clonal B- and T-cell populations. These assays amplify the DNA between primers that target the conserved V regions and the conserved J regions of antigen receptor genes. These conserved regions, where primers target, lie on either side of an area where programmed genetic rearrangements occur during the maturation of all B and T lymphocytes. Different populations of the B and T lymphocytes arise as a result of these genetic rearrangements.
The antigen receptor genes that undergo rearrangements are the immunoglobulin heavy chain (IGH) and light chain loci (IGK and IGL) in B-cells, and the T-cell receptor gene loci (TRA, TRB, TRG and TRD) in T-cells. Each B- and T-cell has one or two productive V–J rearrangements that are unique in both length and sequence. Therefore, when DNA from a normal or polyclonal population is amplified using DNA primers that flank the V-J region, amplicons that are unique in both sequence and length are generated, reflecting the heterogeneous population. In some cases, where lymphocyte DNA is not present, no amplicons will be generated. Samples containing TRB clonal populations yield up to four prominent amplified products of the same length and sequence that are detected with significant frequency of occurrence, within a diminished polyclonal background amplified at a lower frequency.
PCR amplicons are purified to remove excess primers, nucleotides, salts, and enzymes using the Agencourt® AMPure® XP system. This method utilizes solid-phase reversible immobilization (SPRI) paramagnetic bead technology for high-throughput purification of PCR amplicons. Using an optimized buffer, PCR amplicons that are 100 bp or larger are selectively bound to paramagnetic beads while contaminants such as excess primers, primer dimers, salts, and unincorporated dNTPs are washed away. Amplicons can then be eluted and separated from the paramagnetic beads resulting in a more purified PCR product for downstream analysis and amplicon quantification.
Purified amplicons are quantified using the KAPA Library Quantification Kits for Illumina platforms. Purified and diluted PCR amplicons and a set of six pre-diluted DNA standards are amplified by qPCR methods, using the KAPA SYBR® FAST qPCR Master Mix and primers. The primers in the KAPA kit target Illumina P5 and P7 flow cell adapter oligo sequences.
The average Ct score for the pre-diluted DNA Standards are plotted against log10 to generate a standard curve, which can then be used to calculate the concentration (nM) of the PCR amplicons derived from sample DNA. Calculating the concentration of PCR amplicons allows equal amplicon representation in the final pooled library that is loaded onto the MiSeq® for sequencing.
Next-Generation Sequencing (NGS)
Sanger sequencing methods represent the most popular in a range of ‘first-generation’ nucleic acid sequencing technologies. Newer methods, which leverage massively parallel sequencing approaches, are often referred to as Next-Generation Sequencing (NGS). NGS technologies can use various combination strategies of template preparation, sequencing, imaging, and bioinformatics for genome alignment and assembly.
NGS technologies used in this product rely on the amplification of genetic sequences using a series of consensus forward and reverse primers that include adapter and index tags. Amplicons generated with this LymphoTrack master mixes are quantified, pooled, and loaded onto a flow cell for sequencing with an Illumina MiSeq sequencing platform. Specifically, the amplified products in the library are hybridized to oligonucleotides on a flow cell and are amplified to form local clonal colonies (bridge amplification). Four types of reversible terminator bases (RT-bases) are added and the sequencing strand of DNA is extended one nucleotide at a time. To record the incorporation of nucleotides, a CCD camera takes an image of the light emitted when fluorescently labeled nucleotides are added to the sequencing strand. A terminal 3’ blocker is added after each cycle of the sequencing process and any unincorporated nucleotides are removed prior to the addition of four new RT-bases.
This product was designed to allow for two different levels of multiplexing in order to reduce costs and time for laboratories. The first level of multiplexing originates from the multiple indices that are provided with the assays, up to 24. Each of these 24 indices acts as a unique barcode that allows amplicons from individual samples to be pooled together after PCR amplification to generate the sequencing library. Later, the resulting sequences can be sorted by the bioinformatics software to identify those that originated from an individual sample.
The second level of multiplexing originates from the ability of the accompanying software to sort sequencing data by both index and target. This allows amplicons generated with targeted primers (even those tagged with the same index) to be pooled together to generate the library to be sequenced on a single flow cell. An example would be to sequence a combination of products from several Invivoscribe LymphoTrack Assay kits for the MiSeq® such as IGHV Leader, IGH FR1, IGH FR2, IGH FR3, IGK, TRB and TRG together. When multiplexing amplicons of different gene targets it is important to use the appropriate sequencing chemistry. The number of sequencing cycles must be sufficient to sequence the largest amplicon in the multiplex. For example, when multiplexing a combination of IGH FR1, IGH FR2, IGH FR3, IGK, TRB and TRG amplicons together, the MiSeq v2 (500 cycle) or v3 (600 cycle) sequencing kit should be used. When multiplexing any of these amplicons together with IGHV Leader, the MiSeq® v3 (600 cycle) sequencing kit should be used. If multiplexing only IGH FR3 and TRG amplicons together, which both have shorter amplicon sizes, MiSeq v2 (300 or 500 cycle) sequencing kits can be used, but the cycle settings must be adjusted in the sample sheet. For further instructions, please refer to the instructions for use (IFU).
The number of samples that can be multiplexed onto a single flow cell is also dependent on the flow cell that is utilized. Illumina’s standard flow cells (MiSeq v3) can generate 20-25 million reads. To determine the number of reads per sample, divide the total number of reads for the flow cell by the number of samples that will be multiplexed. Illumina also manufacturers other flow cells that utilize the same sequencing chemistry, but generate fewer reads. When using these alternative flow cells one must consider that fewer total reads either means less depth per sample or fewer samples can be run on the flow cell to achieve the same depth per sample.
Minimal Residual Disease Evaluation
NGS-based minimal residual disease (MRD) testing is a proven tool that aids in the development of treatment strategies for hematologic malignancies. The LymphoTrack Clonality Assays can be used with the LymphoTrack MRD Software (Catalog # 75000008), LymphoQuant® Internal Controls and LymphoTrack Low Positive Controls to objectively track up to five clonal rearrangements in longitudinal studies with up to 10^-6 sensitivity. For more information on our bundled MRD solution email email@example.com or visit www.invivoscribe.com/mrd-clonality.
This RUO assay tests genomic DNA. The minimum input quantity is 50 ng of high quality DNA.
1. Miller JE, et al. (2013) Molecular Genetic Pathology (2nd Edition., sections 184.108.40.206 and 220.127.116.11).
2. Tonegawa, S, et al. (1983) Nature. 302, 575-581.
3. Trainor, KJ, et al. (1990) Blood. 75, 2220-2222.
This product is for Research Use Only; not for use in diagnostic procedures.
This product is covered by one or more patents and patent applications owned by or exclusively licensed to Invivoscribe, Inc., including United States Patent Number 7785783, United States Patent Number 8859748, United States Patent Number 10280462, European Patent Number EP 1549764B1 (validated in 16 countries, and augmented by related European Patents Numbered EP2418287A3 and EP 2460889A3), Japanese Patent Number JP04708029B2, Japanese Patent Application Number 2006-529437, Brazil Patent Application Number PI0410283.5, Canadian Patent Number CA2525122, Indian Patent Number IN243620, Mexican Patent Number MX286493, Chinese Patent Number CN1806051, and Korean Patent Number 101215194.
Use of this product may require nucleic acid amplification methods such as Polymerase Chain Reaction (PCR). Any necessary license to practice amplification methods or to use reagents, amplification enzymes or equipment covered by third party patents is the responsibility of the user and no such license is granted by Invivoscribe, Inc., expressly or by implication.
©2024 Invivoscribe, Inc. All rights reserved. The trademarks mentioned herein are the property of Invivoscribe, Inc. and/or its affiliates, or (as to the trademarks of others used herein) their respective owners.
ILLUMINA® and MiSeqTM are registered trademarks of Illumina, Inc.